Compounds that demonstrate chelation affinity and selectivity for first
transition series elements are administered to patients suffering from
such conditions as ischemia, prolonged seizures and trauma to provide
neuroprotection, cardioprotection, or both. These compounds when
administered form complexes with chelatable iron and copper cations and
thereby mitigate the ability of these cations to catalyze Haber-Weiss
reactions that form toxic hydroxy free radicals that cause tissue injury.
These compounds also form complexes with chelatable zinc cations thereby
inhibiting the cytotoxicity associated with excess chelatable zinc.